Navigation Links
Abbott Opens New State-of-the-Art R&D Facility to Help Bring Medicines to Patients Faster
Date:6/12/2008

begins shortly after a candidate molecule is identified. Initial formulations are then refined as more information is gathered through the development process.

The center was specifically designed with cutting-edge equipment and improvements to advance the R&D process, including automated technologies that reduce the time for preparing, producing and refining pilot drug formulations. In addition, all of the equipment in the facility is aligned with the production equipment in Abbott's commercial manufacturing sites, which will allow for rapid scale-up of production as drug compounds move toward late-stage clinical trials and market availability for patients.

"We considered several locations for the new formulation center, but decided to strategically place the building in the midst of our other Abbott Park R&D facilities to provide easy access for our scientists, pharmacists and engineers," said Leonard.

Fast Facts for Abbott's New Formulation Development Center

-- Location: Abbott Park, Ill.

-- Size and structure: Two-story, 64,000-square-foot facility features a

flexible design with modular walls and ceilings that will allow for

rapid future expansion

-- Key Current Formulation Programs: Currently developing oral

formulations (capsule and tablet) for clinical studies involving new

compounds to treat cancer, hepatitis, pain and other areas

-- Investment: $53 million

-- Facility Initiated/Completed: Groundbreaking in June 2005; Completed in

January 2008

-- Personnel: Seventeen dedicated onsite employees; more than 40

additional staff regularly work in the facility

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... The Law Offices of Ben C. ... claims dealing with Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter ... Cook IVC Filter clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales ...
(Date:8/4/2015)... ... August 04, 2015 , ... In the most recent ... & Johnson report that a new location for pretrial proceedings is under consideration, ... and cancer warning information at their website, the Talcum Powder Cancer Lawsuit Center. ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... independent educational grants in support of an interaction simulation session entitled "NOACS: What ... is jointly provided by Medical Learning Institute Inc. and EDUmotion US LLC. , ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... press at its Denver facility that will usher in a new standard of ... Lightning Labels more effectively meet its twin objectives of quality and quantity ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... "The Winscribe Text results have been impressive so far". , Mr Cauchois ... management from Winscribe's French sales partner Dicma and the healthcare technology offered by ...
Breaking Medicine News(10 mins):Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4
... published whole-genome sequences of not just one, but two supercentenarians, ... common genetic phenomena contribute to the genetic background of extreme ... by researchers from the Boston University Schools of Public Health ... to researchers around the world at the NIH data repository. ...
... are studying biomarkers substances present in spinal fluid and ... 140 people with mild memory impairment, showing that a certain ... high levels of the substance tau) indicate a high risk ... as 91 per cent of the patients with mild memory ...
... , MONDAY, Jan. 2 (HealthDay News) -- A small study ... as a treatment for general depression, may also help patients ... surgery necessary to allow deep brain stimulation is extremely expensive. ... early to know for sure if the treatment is appropriate ...
... A hormone derived from visceral fat called adiponectin may play ... dementia and Alzheimer disease (AD) in women, according to a ... , one of the JAMA/Archives journals. The number of ... the next 20 years from the current number of about ...
... , MONDAY, Jan. 2 (HealthDay News) -- Searching for ... found a marker of change in the brain that precedes the ... indicator of trouble to come, they say, is a shift in ... the brain and spinal cord. Among patients already diagnosed with mild ...
... whether or not you will develop exfoliation syndrome (ES) -- ... open-angle glaucoma and increased risk of cataract as well as ... does matter. "Although many studies from around the world ... of the basic descriptive epidemiologic features, which may help shed ...
Cached Medicine News:Health News:Genetic predisposition to disease common in 2 supercentenarians: New study 2Health News:Alzheimer's damage occurs early 2Health News:Study Looks at Deep Brain Stimulation in Bipolar Patients 2Health News:Study Looks at Deep Brain Stimulation in Bipolar Patients 3Health News:Study finds another potential risk factor for developing dementia and Alzheimer's disease in women 2Health News:Changes in Cerebrospinal Fluid May Signal Early Alzheimer's 2Health News:Outside temperatures, sun exposure and gender may trigger glaucoma 2Health News:Outside temperatures, sun exposure and gender may trigger glaucoma 3
(Date:8/3/2015)... , August 3, 2015 ... by Persistence Market Research "Global Market Study on ... to Witness Highest Growth by 2022", the global physiotherapy ... Bn by the end of 2015 and is expected ... 2015 to 2022, to account for US$23.7 Bn by ...
(Date:8/3/2015)... 3, 2015  CytRx Corporation (NASDAQ: CYTR ), ... today reported financial results for the three months ended ... recent accomplishments and upcoming milestones for its clinical development ... been very productive for CytRx. Enrollment in our ongoing ... soft tissue sarcoma (STS) continues on track to be ...
(Date:8/3/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ... and full year of its fiscal year ended ... Executive Officer of Array, noted, "Binimetinib and encorafenib, two ... track for regulatory submissions in 2016. Additional data ... BRAF-mutant colorectal cancer further validate the value of ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... Feb. 10 Choosing foods bearing the organic label ... products they buy have been produced without the use of antibiotics, ... CBS Evening News with Katie Couric segment on livestock ... recognize and respect the powerful nature of antibiotics. As a result, ...
... , Evaluate Analgesic Efficacy and Safety ... Following Total Knee Replacement Surgery , SYDNEY ... QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced ... (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, ...
Cached Medicine Technology:Organic Is Answer to Those Seeking Foods Produced Without Antibiotics 2Organic Is Answer to Those Seeking Foods Produced Without Antibiotics 3QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission 2QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission 3QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission 4QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission 5
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
... Maximum, Maximum Xtra, and Maximum ACT ... standard and specialty hemostasis introducers in ... the premier hemostasis introducers for use ... including angiography, angioplasty, stenting, atherectomy, temporary ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
Rapid Exchange Stent Delivery System with Hepacoat...
Medicine Products: